


Please type a plus sign (+) inside this box → ☐



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## TRANSMITTAL FORM

to be used for all correspondence after initial filing)

Application Number	09/673,707	
	Filing Date	January 11, 2001
	First Named Inventor	Pastan, Ira H.
	Group Art Unit	1645
	Examiner Name	Zeman, Robert A.
Total Number of Pages in This Submission	Attorney Docket Number	015280-356100US

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Response to Notice to Comply/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, Communication Under 37 CFR 1.821-1.825, paper copy of Seq. Listing, CRF of Seq. Listing, copy of Notice to Comply
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Laurence J. Hyman	Reg. No. 35,551
Signature		
Date	December 5, 2002	

RECEIVED

DEC 16 2002

TECH CENTER 1600/2900

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:	
12/5/02	
Typed or printed name	Patricia Andrews
Signature	
Date	12/5/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1412526 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

**PATENT**  
Attorney Docket No.: 015280-356100US  
Client Reference No.: E-201-98/2

Assistant Commissioner for Patents  
Attn: Box Sequence Listing  
Washington, D.C. 20231

On Dec. 5, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Patricia Andrews

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

PASTAN et al.

Application No.: 09/673,707

Filed: January 11, 2001

For: RECOMBINANT IMMUNOTOXIN  
DIRECTED AGAINST THE HIV-1  
GP120 ENVELOPE GLYCOPROTEIN

Examiner: Zeman, Robert A.

Art Unit: 1645

TRANSMITTAL LETTER –  
RESPONSE TO NOTICE TO COMPLY

Attn: Box Missing Parts  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**

**DEC 16 2002**

**TECH CENTER 1600/2900**

Sir:


Pursuant to the Notice to Comply, dated November 5, 2002, enclosed are the following to be made of record in the above-identified application:

- 1) Communication Under 37 CFR 1.821-1.825 and Amendment
- 2) Copy of Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence  
Disclosures
- 3) Computer readable form of Sequence Listing
- 4) Paper copy of the Sequence Listing

Please charge Deposit Account No. 20-1430 for the response to notice to comply surcharge.

The Commissioner is hereby authorized to charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to Deposit Account No. 20-1430. This Transmittal Letter is submitted in triplicate.


Respectfully submitted,

  
Laurence J. Hyman  
Reg. No. 35,551

**Customer No. 20350**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415 576-0300  
LJH:pja

SF 1412505 v1



Application No.: **673,707**

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. §.133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: the specification and claims recite compounds whose identifiers incorporate sequences (PE38KDEL etc). These identifiers are not in compliance with the sequence requirements.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
PatentIn Software Program Support

Technical Assistance.....703-287-0200  
To Purchase PatentIn Software.....703-306-2600

**RECEIVED**

DEC 16 2002

TECH CENTER 1600/2900

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**